Clinical trialPhase 2Completed
BrUOG 295: Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
BrUOG 295:Adjuvant FOLFOX-A For Resected Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 1 February 2014
- Ended
- 17 March 2022
- Enrollment
- 25 participants
- Sites
- 2
- Primary outcomes
- Feasibility of Adjuvant FOLFOX-A
- Sponsor type
- Academic / other
- Results posted
- 8 September 2021
- Last update
- 1 June 2022
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 1 June 2022
- Primary outcome
- Feasibility of Adjuvant FOLFOX-AFOLFOXA: 18 of 24Values: ParticipantsTime frame: Up to 24 weeksNo analysis posted for this outcome (outcome 1)
- Participants
- FOLFOXA: 25 started, 24 completed
- Serious adverse events
- FOLFOXA: 1 of 25Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
- DFS/RFS · Disease-free Survival
- 6 months after completion of drug: FOLFOXA 23/24 [Participants] (first of 4 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
The investigators preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX and appears to be better tolerated. Therefore, FOLFOX-A may be a better regimen in the adjuvant setting for patients with resected pancreatic cancer. This protocol will obtain preliminary data on safety and disease-free and overall survival following administration of FOLFOX-A for patients with resected pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
See summary above
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Feasibility of Adjuvant FOLFOX-A [Up to 24 weeks]. Count Of Participants, Participants. FOLFOXA (n=24): 18.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Disease-free Survival [Through study completion, an average of 3 years.]. Count Of Participants, Participants. 6 months after completion of drug: FOLFOXA (n=24): 23. 12 months after completion of drug: FOLFOXA (n=24): 15. 24 months after completion of drug: FOLFOXA (n=24): 12. 36 months after completion of drug: FOLFOXA (n=24): 8.